Overexpression of LINC00880 promotes colorectal cancer growth

作者: Ge Gao, Peiwen Xu, Chunyu Yang, Mengyuan Qian, Qingwen Wang, Surui Yao, Yuan Yin, Zehua Bian
杂志: Transl Cancer Res
Doi: https://www.doi.org/10.21037/tcr-2025-54
出版日期: 2025-05-23

论文中使用的产品/服务

摘要

Background: Research has revealed that long non-coding RNAs (lncRNAs) are intimately associated with the occurrence, development, and metastasis of tumors through their regulation of gene expression. The lncRNA LINC00880 is important for colorectal cancer (CRC) occurrence and development. Our research aimed to explore the roles of LINC00880 in CRC progression.

Methods: The expression of LINC00880 in CRC cells and tissues was first measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and the prognosis of CRC patients was then investigated using the Kaplan-Meier method. The impacts of LINC00880 on CRC growth were evaluated by a series of in vitro and in vivo assays. Mechanistically, RNA sequencing (RNA-seq) technology and transcriptome analysis experiments were employed to validate the impact of LINC00880 on cell cycle pathway.

Results: In this study, we have demonstrated, for the first time, that LINC00880 is significantly overexpressed in CRC and is associated with poor patient survival. Functional assays indicated that LINC00880 promotes the growth of CRC cells both in vitro and in vivo. Furthermore, RNA-seq has revealed the impact of LINC00880 on the cell cycle and DNA replication pathways, and identified MCM3 as a potential downstream target of LINC00880.

Conclusions: Our findings indicate that LINC00880 is upregulated in CRC and promotes tumor growth.

文章链接

关于派真

作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。

凭借我们独立知识产权的π-alpha^TM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。